Description
Composition- Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin 500 mg
Mode of Action- Combines incretin enhancement, renal glucose excretion and insulin sensitization for comprehensive multi-pathway glycemic control.
USPs- Triple antidiabetic mechanism; useful in uncontrolled type 2 diabetes; supports fasting and postprandial glucose reduction.
Prescribing Specialties- Diabetologist, Internal Medicine
